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Abstract
Background: In order to validate if the test result of the Chemotherapy Resistance Test (CTR-Test) is able to predict
the resistances or sensitivities of tumors in ovarian cancer patients to drugs, the CTR-Test result and the corresponding
clinical response of individual patients were correlated retrospectively. Results were compared to previous recorded
correlations.
Methods: The CTR-Test was performed on tumor samples from 52 ovarian cancer patients for specific chemotherapeutic
drugs. Patients were treated with monotherapies or drug combinations. Resistances were classified as extreme (ER),
medium (MR) or slight (SR) resistance in the CTR-Test. Combination treatment resistances were transformed by a scoring
system into these classifications.
Results: Accurate sensitivity prediction was accomplished in 79% of the cases and accurate prediction of resistance in
100% of the cases in the total data set. The data set of single agent treatment and drug combination treatment
were analyzed individually. Single agent treatment lead to an accurate sensitivity in 44% of the cases and the drug
combination to 95% accuracy. The detection of resistances was in both cases to 100% correct. ROC curve analysis
indicates that the CTR-Test result correlates with the clinical response, at least for the combination chemotherapy.
Those values are similar or better than the values from a publication from 1990.
Conclusions: Chemotherapy resistance testing in vitro via the CTR-Test is able to accurately detect resistances in
ovarian cancer patients. These numbers confirm and even exceed results published in 1990. Better sensitivity detection
might be caused by a higher percentage of drug combinations tested in 2012 compared to 1990. Our study confirms
the functionality of the CTR-Test to plan an efficient chemotherapeutic treatment for ovarian cancer patients.
Keywords: CTR-test, Individualized cancer therapy, Ovarian cancer, Sensitivity and resistance prediction, Resistance
classification system
Background
Ovarian cancer is one of the leading causes of cancer-
related death in women. According to the Robert Koch-
Institut, in 2012 in Germany 7380 women were newly
diagnosed with ovarian cancer. Worldwide in 2012 there
were about 239,000 new ovarian cancer patients (according
to World Cancer Research Fund International). Numerous
patients show advanced stages due to a late diagnosis.
Therefore the prognosis is rather poor and the relative 5
year survival rate is only about 41% (Robert Koch-Institut,
2012). Furthermore, the recurrence rate is very high (around
70%) [1, 2]. The standard first-line treatment for ovarian
cancer is cytoreductive surgery followed by a combination
chemotherapy with carboplatin and paclitaxel [2–5].
However, several studies indicate, that tumor cells ex-
hibit a different chemosensitivity to chemotherapeutics
in distinct patients which influences the clinical outcome
of a chemotherapy [6–11]. Therefore, standard treat-
ments can be ineffective in single patients because of
* Correspondence: frank.kischkel@therapyselect.de
Frank Christian Kischkel, Carina Meyer and Julia Eich are joint first authors.
†Equal contributors
1TherapySelect, Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kischkel et al. Journal of Ovarian Research  (2017) 10:72 
DOI 10.1186/s13048-017-0365-9
drug resistance of the tumor and a next-line therapy is
needed due to a relapse. Thus, it is useful to identify in
vitro the resistance profile of a set of chemotherapeutics
which are considered for the individual patient, before a
potential ineffective chemotherapy is applied [12].
Thereby, the therapeutic benefit can be increased, un-
necessary toxicity is avoided, costs are reduced and valu-
able time is saved [7, 13].
In 1990 Kern and Weisenthal introduced a resistance
classification system based on in vitro testing of living
tumor material. They analyzed 450 tumor samples in
vitro via the EDR (extreme drug resistance) assay to find
the particular resistance of patients and compared those
results to the actual treatment success of the individual
patients [6]. The EDR assay shows a > 99% accuracy in
detecting chemotherapeutics that are ineffective and do
not result in a clinical benefit for an individual patient
[6].
The CTR-Test®, which was employed in this paper, is
identical to the EDR assay. The objective of this paper was
to demonstrate functionality as well as usefulness of the
CTR-Test regarding prediction of clinical response to
drugs in ovarian cancer. We used 52 ovarian cancer sam-
ples and tested them via the CTR-Test to identify the drug
resistance of the individual patients to specific chemother-
apeutics applied as single drugs or in combination. The re-
sults from the CTR-Test were compared to the clinical
response of the patients. Furthermore, our data were com-
pared to the data from Kern and Weisenthal [6].
Methods
Patients
During the time span January 2010 – January 2011 96
female ovarian cancer patients were included in this
study. Therefore, fresh tumor material from the patients
was sent to TherapySelect from the Charité in Berlin
within 24 h to perform the CTR-Test, which tests the
drug resistance in vitro. A retrospective single-blinded
study was performed. The treating physicians received
the CTR-Test results before therapy, which could be
used by the physicians for therapy planning. The company
performing the CTR-Test was blinded to the response
rate. The response rate of the used chemotherapeutic drug
was compared to the result of the CTR-Test. Only 52 pa-
tients could be included in this study. The other patients
were excluded because in 12 cases there was no chemo-
therapy treatment applied or it was not clear which drug
was chosen. In 11 cases there was no CTR-Test result
available (due to insufficient tumor material) and in 17
cases a chemotherapeutic drug was chosen which was not
tested by the CTR-Test. In 4 cases no or no clear follow
up was available. In the remaining cases the CTR-Test re-
sults were classified into resistance classes and the treat-
ment success was defined.
Resistance and treatment response classification
The CTR-Test determines the percent cell growth inhib-
ition (PCI) values and those are classified into 3 different
classes. These are: extreme resistance (ER) with a
PCI ≤ mean – 1 SD, medium resistance (MR) with a PCI
between mean and mean – 1 SD and slight resistance
(SR) with a PCI ≥ mean. The mean and the standard de-
viation are determined by the PCI values of several sam-
ples treated with the chosen drug.
The patients were classified as responder or non-
responder depending on the clinically evaluated treat-
ment success. Treatment success was determined by
physician’s evaluation. Physicians assessed disease out-
comes at follow-up visits on the available clinical data
including imaging techniques (like CT-scans), CA125
levels, physical examinations and medical records. The
response classifications were extracted from the med-
ical records as is. The responders are defined as clinical
complete response or partial response, whereas the
non-responders showed clinical stable disease or pro-
gressive disease.
CTR-test
The CTR-Test was performed regarding published pro-
tocols [6, 14]. Following surgery the tumor samples were
immediately immersed in incubation medium and sent
promptly to laboratory. Tumor specimens were minced
with sharp surgical scissors and then subjected to en-
zymatic digestion using 0.14% collagenase type I and
0.01% DNAse. The resulting small aggregates (spheroids)
and single cells were centrifuged and the pellet was sus-
pended in 5 ml of minimum-essential tissue culture
medium containing heat-inactivated fetal calf serum,
100 units of penicillin, 100 μg/ml of streptomycin and
200 mM L-glutamine. Tumor cell percentage and cell
viability was assessed by an external pathology. The cell
viability was between 50% - > 90% and the tumor cell
content was between 40% - 90% (see Additional file 1).
Soft agar matrix (0.4%) selective for tumor growth was
placed in 24-well polystyrene culture dishes and 50 μl of
one specific chemotherapeutic drug was then added to
appropriate wells. The drug concentrations can be found
in [15]. Tumor cells suspended in 0.5 ml tissue culture
medium and 0.2% agarose were then added to each well.
After 72 h incubation at 37 °C in the presence of 5%
CO2, 5.0 μCi H-3-thymidine was introduced into each
well, and the plates were incubated for an additional
48 h to allow radioactive thymidine incorporation into
the DNA of the surviving tumor cells. Cellular DNA was
collected on glass-fiber filters using a PerkinElmer har-
vester. The isotope uptake and the corresponding DNA
amount is determined by scintillation counting. The data
obtained are counts per minute (cpm). Treating cells
with a lethal dose of a drug is used as a positive control
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and no addition of drugs to cells is used as negative con-
trol. The percent cell growth inhibition (PCI) value repre-
sents the effectiveness of the chemotherapeutic. PCI
values are calculated using the formula: PCI = (cpm(treated
cells)-cpm(positive control))/(cpm(negative control)-
cpm(positive control)).
Drugs used for analysis
The to be tested drugs in this study were chosen after
therapeutic relevance and validated before used in the
CTR-Test. Validation was used to find concentrations in
a physiological range and it was performed with tumor
samples to set the concentration to a level which leads
to a satisfying distribution of drug action among a col-
lective of samples.
Statistical analysis
Receiver operator characteristic (ROC) curve analysis
was conducted in R. The 95% confidence intervals for
proportions were determined by the Clopper-Pearson
method.
Results
From 2010 to beginning of 2011 96 ovarian cancer pa-
tients from the Charité Berlin participated in this study
concerning the retrospective diagnostic capacity of the
CTR-Test. Patients were treated regarding the standard
guidelines (according to the Association of the Scientific
Medical Societies in Germany) and tumor samples were
analyzed with the CTR-Test to determine the in vitro re-
sistance of the tumor cells towards the selected chemo-
therapeutic drugs. From those 96 patients, 52 data sets
were suitable to be included in this analysis because in
those cases the CTR-Test presented a result and the pa-
tients received a chemotherapy with a single drug or
drug combination tested by the CTR-Test (Table 1).
Forty-four patients had to be excluded from the study
due to several reasons, which can be found in Table 1
and in the Methods part of this paper.
The remaining 52 patients were treated either with
monotherapies (19 patients) or combination therapies
(33 patients). In the monotherapy group, 3 patients were
treated additionally with Avastin (Table 2).
For each included patient the applied chemotherapy
and the corresponding CTR-Test result were docu-
mented. Additionally, the chemotherapy success was de-
termined by physician’s evaluation and patients were
classified accordingly as responder or non-responder. In
Table 3 the patients are separated in responder or non-
responder and the used chemotherapeutics are listed with
the corresponding CTR-Test results. Furthermore, the dif-
ferent therapy types (monotherapy, monotherapy plus
Avastin, combination therapy) are analyzed individually
(Table 3). According to former publications [6–11], we de-
fined three resistance categories based on the percent cell
growth inhibition (PCI) values of the patients and the
responses were scored. For each drug a heterogeneous pa-
tient population was analyzed for their response to that
particular drug. ER (extreme resistance) is characterized
by PCI < mean – 1SD (standard deviation) and is scored
“0”. PCI values ≥ mean are defined as SR (slight resistance)
and are scored “2”. MR is classified as PCI > ER but <
mean and is scored “1”.
These classifications are comparable with the EDR,
IDR and LDR classes introduced in 1990 by Kern and
Weisenthal [6]. To predict the effect of drug combina-
tions, the two corresponding single measurements are
combined to define the resistance class of the combin-
ation. A scoring system, introduced by [7], is used for
predicting the grade of resistance of a combination
based on the single measurements. Therefore the single
resistance of ER is scored with 0, MR with 1 and SR with
2 and the combination score is accomplished by sum-
ming up both single scores. This creates a range with a
maximum of 4 and a minimum of 0 [7] (Table 3). To
transfer the combination scores back to the resistances
classes, score 4 and 3 are combined to create the class of
SR. Two and one represent the class of MR and 0 is
equal to ER.
The distribution of CTR-Test resistance classes for re-
sponder and non-responder was determined and com-
pared with each other. This was done separately for
monotherapy (Mono), monotherapy plus Avastin
((Mono)) and the combination therapy (Combi) data set.
To get a general picture, the two monotherapy data sets
Table 1 Classification of 96 ovarian cancer patients regarding
their analyzability for the study
Number Analyzability Explanation
52 Analyzable Patients received a traceable chemotherapy and
the used drugs were analyzed by the CTR-Test
44 Not
analyzable
Patients either did not receive a chemotherapy
(12), drugs were used that were not measured
in the CTR-Test (17), the CTR-Test did not yield a
result (11) or no record about chemotherapy or
response is available (4)
Table 2 Classification of 52 analyzable ovarian cancer patients
(see Table 1) into three groups regarding the applied therapy
Number Group name Description of therapy
16 Mono Patients received a monotherapy with
one chemotherapeutic drug
3 (Mono) Patients received a monotherapy with
one chemotherapeutic drug plus a
treatment with Avastin
33 Combi Patients received a combination therapy
with 2 drugs
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Table 3 Clinical response of individual patients after monotherapy, monotherapy plus Avastin or combination therapy
Non-Responder Responder
Patient Substance CTR-Test Patient Substance CTR-Test
Monotherapy
1 Carbo ER 13 Pac SR
2 Caelyx SR 14 Carbo SR
3 Topo SR 15 Topo SR










1 Caelyx + Avastin SR 2 Caelyx + Avastin SR
3 Topo + Avastin MR
Combination Chemotherapy
Patient Substance CTR-Test Scorea Patient Substance CTR-Test Scorea
1 Carbo/Pac ER/ER 0 9 Carbo/Caelyx SR/SR 4
2 Carbo/Caelyx MR/ER 1 10 Carbo/Gem SR/SR 4
3 Carbo/Gem ER/ER 0 11 Carbo/Pac SR/SR 4
4 Carbo/Pac SR/SR 4 12 Carbo/Caelyx SR/ER 2
5 Carbo/Gem ER/ER 0 13 Carbo/Caelyx SR/ER 2
6 Carbo/Pac ER/SR 2 14 Carbo/Caelyx SR/MR 3
7 Carbo/Caelyx MR/ER 1 15 Carbo/Caelyx SR/SR 4
8 Carbo/Pac MR/ER 1 16 Carbo/Pac MR/ER 1
17 Carbo/Pac SR/MR 3
18 Carbo/Caelyx MR/SR 3
19 Carbo/Caelyx SR/SR 4
20 Carbo/Pac SR/MR 3
21 Carbo/Caelyx SR/MR 3
22 Carbo/Gem ER/SR 2
23 Carbo/Pac SR/SR 4
24 Carbo/Caelyx MR/MR 2
25 Carbo/Pac SR/MR 3
26 Carbo/Caelyx MR/MR 2
27 Carbo/Caelyx SR/MR 3
28 Carbo/Pac SR/MR 3
29 Carbo/Pac SR/MR 3
30 Carbo/Pac SR/SR 4
31 Carbo/Pac SR/SR 4
32 Carbo/Pac ER/SR 2
33 Carbo/Caelyx SR/SR 4
The applied chemotherapeutics and the corresponding results of the CTR-Test for individual patients are listed. Patients were classified as non-responders
and responders
Abbreviations: Carbo Carboplatin, Gem Gemcitabine, Pac Paclitaxel, Topo Topotecan, ER extreme resistance, MR medium resistance, SR slight resistance, Caelyx
doxorubicin-hydrochloride in a pegylated liposomal formulation
aFor combination therapy the two single drugs were measured and scores were determined according to the resistance categories: ER = 0; MR = 1; SR = 2. The
scores obtained are 4 = SR/SR; 3 = MR/SR, SR/MR; 2 = ER/SR, SR/ER, MR/MR; 1 = ER/MR, MR/ER; 0 = ER/ER
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(Mono/(Mono)) were combined and then united with
the combination data set.
Comparison of Charité data to Kern and Weisenthal paper
Kern and Weisenthal [6] analyzed the CTR-Test resist-
ance profile of 450 samples from patients with a wide
range of tumor types and compared those with the ac-
tual response rates of chemotherapies in patients. With
defining the extreme resistance (EDR) class, an accuracy
of 99% was achieved in predicting inefficient chemother-
apies correctly (95% CI: 0–4). In 52% of the cases (95% CI:
45–59) the prediction of sensitivity (LDR) was correct,
meaning that the patients did respond to the chosen
chemotherapy and the CTR-Test predicted this outcome
(Table 4) [6]. In contrast to Kern and Weisenthal [6] we
only focused on ovarian cancer. Looking at the total data
set from the Charité Berlin from 2012, the values for
sensitivity and resistance outnumber the total data set
values from 1990 with a sensitivity precision of 79% for
SR (22 responder from 28) (95% CI: 59–92) and an ER
resistance detection of 100% (0 responder from 7) (95%
CI: 0–41) (Table 4). The values for the medium resist-
ance are 16% (95% CI: 9–24) accuracy predicting sensi-
tivity and on the other hand 84% accuracy for
predicting resistances in case of Kern and Weisenthal
(Table 4) [6]. The Charité values for MR are to 53% ac-
curate in sensitivity prediction and to 47% accurate in
resistance prediction (95% CI: 28–77) (Table 4).
Kern and Weisenthal separated their data set into sub-
sets for each cancer type which offers the possibility to
directly compare the response distribution in the setting
of ovarian cancer (No. of patients 46) with the data set
of patients participating in the Charité study (No. of pa-
tients 52) (Table 4). For ovarian cancer in 1990, an ac-
curacy of 100% for resistance in the EDR class (95% CI:
0–28) (100% for the 2012 study, 95% CI: 0–41) and a
58% accuracy in predicting sensitivity in the LDR class
(95% CI: 37–78) (79% for the 2012 study, 95% CI: 59–
92) was reached (Table 4).
The 2012 data set can be separated into distinct
groups of single agent and combination treatment. Both
sets are compared to data from the Kern and Weisenthal
paper [6]. For single agent treatment, values are mea-
sured of 44% SR sensitivity (95% CI: 14–79) (Table 4)
compared to 48% in 1990 (95% CI: 40–56) (Table 4),
MR sensitivity of 33% (95% CI: 4–78) (Table 4) com-
pared to 16% (95% CI: 5–21) (Table 4) and ER resistance
of 100% (95% CI: 0–60) (Table 4) and 99% (95% CI: 0–
5), respectively (Table 4). The single agent analysis is in
our case ovarian cancer specific and consists of 19 differ-
ent patients. In comparison, Kern and Weisenthal ana-
lyzed 345 samples of different tumor types [6].
The second subset is comprised of data derived from
tumor samples treated with a drug combination. Here,
in 2012 values of 95% SR sensitivity (95% CI: 74–100),
64% MR sensitivity (95% CI: 31–89) and 100% ER resist-
ance (95% CI: 0–71) was measured (Table 4) which is
confronted with 1990 values of 61% (95% CI: 48–72),
32% (95% CI: 14–55) and 100% (95% CI: 0–26), respect-
ively (Table 4). In the 2012 combination subset 33 sam-
ples were included and in 1990 105 samples.
A receiver operator characteristic (ROC) curve analysis
for all above mentioned data sets (see Table 4) was per-
formed to confirm the assumption that the CTR-Test is
Table 4 Correlation of CTR-Test results and clinical response and comparison to Kern and Weisenthal data
SR MR ER
Resp. / n %
95% CI
Resp. / n %
95% CI
Resp. / n %
95% CI










































The number of responders (Resp.) among the total number of patients (n) for the three different CTR-Test results are listed. The percentage and the 95% confidence
interval (CI) are indicated
From Kern and Weisenthal 1990, the total data set, ovarian cancer, single agent and combination chemotherapy data are presented. From the Charité Berlin 2012
(see Table 3), the total data set, single agent and combination chemotherapy data are presented
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able to predict the clinical response of patients to a chemo-
therapy treatment (Figs. 1 and 2). As before, our data were
compared to data from [6]. This ROC curve analysis re-
vealed a significant correlation between the CTR-Test
result and the clinical outcome in the case of combination
chemotherapy (Fig. 1), indicated by the good area under
the curve (AUC) value of 0.85 (95% CI: 0.6942–1).
In Fig. 2a the ROC curves of the total data set from
the Charité Berlin 2012 (black curve), the total data set
from [6] (red curve) and the ovarian cancer data from
[6] (green curve) are compared. All three data sets show
good AUC values and a correlation between test result
and response. The AUC for the total data set Charité
Berlin 2012 is 0.7604 (95% CI: 0.6328–0.888); the AUC
for the total data set Kern and Weisenthal 1990 is
0.7904 (95% CI: 0.7565–0.8242); the AUC for the ovar-
ian cancer data set Kern and Weisenthal 1990 is 0.8438
(95% CI: 0.7622–0.9253).
Figure 2b compares the ROC curves of the single
agent chemotherapy from the Charité Berlin 2012 (red
curve) and from Kern and Weisenthal 1990 (black
curve). In contrast to the combination data, the total
data set and the single agent chemotherapy data from
Kern and Weisenthal 1990 (AUC: 0.811, 95% CI:
0.7728–0.8492), the single agent chemotherapy data
from the Charité Berlin do not show a significant correl-
ation between CTR-Test result and response of the pa-
tients (AUC: 0.6923, 95% CI: 0.4741–0.9105).
As mentioned above, the combination chemotherapy
data from the Charité Berlin 2012 show a significant cor-
relation between the CTR-Test result and the clinical
outcome of the patients (AUC: 0.85, 95% CI: 0.6942–1)
(Figs. 1, 2c, red curve). The combination chemotherapy
data from Kern and Weisenthal 1990 also show a good
AUC of 0.6907 (95% CI: 0.6101–0.7713) (Fig. 2c black
curve). In the case of combination chemotherapy, our
test performs better than the test from [6].
Discussion
Our performed study showed a predictive power of the
CTR-Test to detect resistances and sensitivities of ovar-
ian cancer samples from patients treated at the Charité
Berlin to chemotherapeutics prior to chemotherapy.
Sensitivity and resistance is classified via a method intro-
duced in 1990 by Kern and Weisenthal [6]. They ana-
lyzed 450 different tumor samples with the EDR assay
(here called CTR-Test) and accomplished a correct sen-
sitivity detection in 52% (95% CI: 45–59) of the cases
when the EDR assay classified a drug as LDR/SR. It
actually had a positive effect for the patient and was
therefore classified as responder. The prediction of re-
sistances was even more accurate with a 99% (95% CI:
0–4) success rate in the EDR/ER class of detecting cor-
rectly non-responders (Table 4) [6]. In comparison to
those numbers, our newly performed retrospective study
for ovarian cancer at the Charité accomplished a sensi-
tivity rate of 79% (95% CI: 59–92) and a resistance de-
tection of 100% (95% CI: 0–41) (Table 4). Additionally, a
medium resistance class was introduced in 1990 and
within this class Kern and Weisenthal detected correctly
in 16% (95% CI: 9–24) of the cases sensitive substances
(Table 4) [6]. In the data set from the Charité the suc-
cess rate was 53% (95% CI: 28–77) (Table 4). Based on
the 1990 data, a drug with a medium resistance was
more likely to produce no effect in treating the tested
tumor in the patient. Therefore the drug suggestion
would be against such a drug and only drugs from the
SR class should have been recommended. However,
based on the new data from the Charité such a classified
drug has a 53% chance to have an effect. In this case it is
less likely that a drug from the MR class has no effect.
However in both cases it might be better to exclude them
because a not given but effective drug has less severe con-
sequences than an administrated drug with no effect.
The so far presented comparison is between the total
data sets of both studies. In case of the 1990 study sev-
eral different tumor types are included. We only used
samples from ovarian cancer patients. Therefore, it is
Fig. 1 Receiver Operating Characteristic (ROC) curve analysis for the
combination chemotherapy. Tumor samples from 33 ovarian cancer
patients (Charité Berlin, 2012) were used. A CTR-Test was performed
and the patients were treated with a combination chemotherapy
which was measured by the CTR-Test. The individual patients were
evaluated regarding their clinical response (responder or non-
responder) and their CTR-Test result (SR, MR or ER) (see Table 3).
A ROC curve analysis was performed to investigate whether the
CTR-Test is able to predict the clinical response. The corresponding
area under the curve (AUC) value is 0.85 and the 95% confidence
Interval (CI) is 0.6942–1
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useful to also compare the Charité data with the ovarian
cancer data set from Kern and Weisenthal. For this sub-
set a sensitivity in the SR class of 58% (95% CI: 37–78)
was measured, which is slightly closer to the Charité
value of 79%. The ER prediction is in both cases in 100%
(95% CI Charité: 0–41; 95% CI Kern and Weisenthal: 0–
28) of the cases correct. However, the MR discrepancies
are remaining and even became more extreme (0% (95%
CI: 0–28) to 53% (95% CI: 28–77)), making a clear pre-
diction for MR drugs quite complicated (Table 4) [6].
However, in the ovarian cancer data from Kern and
Weisenthal it is not clear how high the percentage of sin-
gle drug agents compared to combination treatment is [6].
It seems that the ratio of single drug to combination
treatment is a determining factor for the accuracy of the
total data set. This conclusion occurs by looking at the
combination and single drug treatment individually. Bet-
ter sensitivity detection might be caused by a higher per-
centage of drug combinations tested in 2012 compared
to 1990. For the single agent correlation the data set of
Kern and Weisenthal [6] is quite similar to the data set
from the Charité (Table 4). The accuracy for SR sensitiv-
ity is at 48% (95% CI: 40–56) (Table 4) and 44% (95% CI:
14–79) (Table 4), respectively. Looking at the correlation
for the combination, a higher percentage is measured in
Fig. 2 Receiver Operating Characteristic (ROC) curve analysis for the
total data set, the single chemotherapy, the combination chemotherapy
and the data sets from Kern and Weisenthal. a Tumor samples from 52
ovarian cancer patients (total data set Charité Berlin, 2012) were used. A
CTR-Test was performed and patients were treated with a monotherapy,
a monotherapy plus Avastin or a combination chemotherapy which
was tested by the CTR-Test. The individual patients were evaluated re-
garding their clinical response (responder or non-responder) and their
CTR-Test result (SR, MR or ER) (see Table 3). A ROC curve analysis was
performed for our total data set and for data from Kern and Weisenthal
1990 (total data set and ovarian cancer) to investigate whether the CTR-
Test is able to predict the clinical response. AUC total data set Charité
Berlin 2012: 0.7604; 95% CI: 0.6328–0.888. AUC total data set Kern and
Weisenthal 1990: 0.7904; 95% CI: 0.7565–0.8242. AUC ovarian cancer
Kern and Weisenthal 1990: 0.8438; 95% CI: 0.7622–0.9253. b Tumor
samples from 19 ovarian cancer patients (Charité Berlin, 2012) were
used. A CTR-Test was performed and the patients were treated with a
monotherapy or a monotherapy plus Avastin. The monotherapy was
tested by the CTR-Test. Patients were evaluated as described above. A
ROC curve analysis was performed for our data and for data from Kern
and Weisenthal 1990 (single agent chemotherapy). AUC single agent
chemotherapy Kern and Weisenthal 1990: 0.811; 95% CI: 0.7728–0.8492.
AUC single agent chemotherapy Charité Berlin 2012: 0.6923; 95% CI:
0.4741–0.9105. c Tumor samples from 33 ovarian cancer patients
(Charité Berlin, 2012) were used. A CTR-Test was performed and the
patients were treated with a combination chemotherapy which was
tested by the CTR-Test. The patients were evaluated as described above.
A ROC curve analysis was performed for our data and for data from
Kern and Weisenthal 1990 (combination chemotherapy). AUC
combination chemotherapy Kern and Weisenthal 1990: 0.6907; 95% CI:
0.6101–0.7713. AUC combination chemotherapy Charité Berlin 2012:
0.85; 95% CI: 0.6942–1
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both cases with 61% (95% CI: 48–72) (Table 4, SR for
combination, 1990) compared to 48% (95% CI: 40–56)
(Table 4, SR for single drugs, 1990) and 95% (95% CI:
74–100) (Table 4, SR for combination, Charité 2012) to
44% (95% CI: 14–79, SR for single drugs, Charité 2012)
(Table 4) in the SR class. The same is seen for the MR
determination, the sensitivity is to 32% (95% CI: 14–55)
accurate for the combination in 1990 (Table 4) com-
pared to the single agent with a percentage of 16% (95%
CI: 5–21) (Table 4) [6]. In 2012 for MR the accuracy is
in general higher but the trend is the same with 64%
(95% CI: 31–89) (Table 4) for the combination and 33%
(95% CI: 4–78) (Table 4) for the single agent therapy.
Here in this paper we measured the two individual
drugs of a drug combination separately. We added the
two scores of the single measurements to obtain the
score and the resistance class of the combination. We
recently published a paper where we described an in
vitro system to predict the chemotherapeutic efficacy of
drug combinations [15]. With this system it is possible
to use single measurements to predict the efficacy of
drug combinations in certain cases and to measure com-
binations directly. However, this system was not yet
available when the samples for this paper were analyzed.
By measuring the drug combinations directly with our in
vitro system our data could have probably been
improved.
A ROC curve analysis confirmed our assumption that
the CTR-Test is able to predict the clinical response of a
patient to a chemotherapy. Our data are comparable to
the data from [6]. In the case of combination chemo-
therapy, our data even exceed their data. Treatment with
a drug combination leads to a reduced resistance risk.
The two used chemotherapeutics normally attack differ-
ent target mechanism and therefore, the chances of de-
veloping a resistance is reduced [16–19].
All data sets from [6] show good AUC values and
therefore their test result correlates with the clinical re-
sponse. The total data set and the combination chemo-
therapy data set from the Charité Berlin 2012 also
indicate a correlation between CTR-Test result and clin-
ical response. The single chemotherapy data from the
Charité do not show a significant correlation, which
could be explained by a too small number of patients
that received a monotherapy.
Conclusions
In conclusion, our study in 2012 confirms and exceeds
the results obtained in 1990. Important to note is that
this study was performed only with 52 ovarian cancer
samples and it is a retrospective study. To reinforce
these findings a prospective study with a bigger sample
size should be performed. Nevertheless, this study is in
line with several different performed studies, suggesting
the use of the CTR-Test as a suitable diagnostic test to
find the right treatment plan for ovarian cancer and
other tumor types.
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